SANGAMO THERAPEUTICS, INC. Income (Loss) from Continuing Operations before Income Taxes, Domestic
SANGAMO THERAPEUTICS, INC. (SGMOQ) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$123.97 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-03-30
- SANGAMO THERAPEUTICS, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$123.97M.
- SANGAMO THERAPEUTICS, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$103.73M.
- SANGAMO THERAPEUTICS, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was -$173.38M.
- SANGAMO THERAPEUTICS, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was -$216.57M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month |
|---|---|
| 2025-12-31 | -$123.97M 10-K · filed 2026-03-30 |
| 2024-12-31 | -$103.73M 10-K · filed 2026-03-30 |
| 2023-12-31 | -$173.38M 10-K · filed 2025-03-17 |
| 2022-12-31 | -$216.57M 10-K · filed 2024-03-13 |
| 2021-12-31 | -$185.22M 10-K · filed 2024-03-13 |
| 2020-12-31 | -$126.62M 10-K · filed 2023-02-23 |
| 2019-12-31 | -$77.35M 10-K · filed 2022-02-24 |
| 2018-12-31 | -$65.69M 10-K · filed 2021-02-24 |
| 2017-12-31 | -$54.57M 10-K · filed 2020-02-28 |
| 2016-12-31 | -$71.67M 10-K · filed 2019-03-01 |